Tirzepatide and semaglutide are the two most closely watched compounds in metabolic medicine research. This page compares their clinical trial weight reduction and glycaemic data head-to-head — including the first direct head-to-head trial, SURMOUNT-5 — and explains the mechanistic basis for their differences.
The Mechanistic Difference: Why Tirzepatide Produces More Weight Loss
Semaglutide activates only the GLP-1 receptor (GLP-1R) — a selective agonist. Tirzepatide is a dual agonist at both GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). It was engineered as a single synthetic peptide with balanced co-agonism at both receptors — not a mixture of two drugs, but one molecule designed to activate both simultaneously.
The GIP receptor component adds several mechanisms that are absent with selective GLP-1R agonism. GIPR is highly expressed in adipose tissue and activates lipolytic and thermogenic pathways that GLP-1R does not directly engage. GIPR activation in hypothalamic circuits may also enhance GLP-1R-mediated appetite suppression through synergistic signalling — some preclinical data suggests GIPR agonism potentiates rather than simply adds to GLP-1R effects. The net result is greater total weight reduction at maximal doses than selective GLP-1R agonism alone.
Obesity Trial Data: SURMOUNT vs STEP
| Trial | Drug | Population | Duration | Mean weight reduction | Key finding |
|---|---|---|---|---|---|
| STEP-1 (2021) | Semaglutide 2.4mg SC weekly | Obese, non-T2D | 68 weeks | −14.9% | Established semaglutide as standard-of-care for obesity pharmacotherapy |
| STEP-2 (2021) | Semaglutide 1mg SC weekly | Obese + T2D | 68 weeks | −9.6% | Lower dose; T2D population; less weight reduction as expected |
| SURMOUNT-1 (2022) | Tirzepatide 5/10/15mg SC weekly | Obese, non-T2D | 72 weeks | −15.0 / −19.5 / −20.9% | 15mg dose: 20.9% mean reduction, 37% of participants lost ≥25% |
| SURMOUNT-2 (2023) | Tirzepatide 10/15mg SC weekly | Obese + T2D | 72 weeks | −13.4 / −15.7% | Greater weight reduction than semaglutide in T2D population |
| SURMOUNT-5 (2025) | Tirzepatide vs Semaglutide 2.4mg | Obese, non-T2D | 72 weeks | ~−20.2% vs −13.7% | First head-to-head trial: tirzepatide statistically superior |
SURMOUNT-5 is the definitive trial for the research community — the first prospective, randomised, head-to-head comparison between maximally-dosed tirzepatide and semaglutide 2.4mg in identical populations and durations. The approximately 6–7 percentage point absolute difference in mean weight reduction at 72 weeks represents a clinically and statistically significant advantage for tirzepatide, consistent with the mechanistic prediction from dual GIP+GLP-1R co-agonism.
Type 2 Diabetes Trial Data: SURPASS vs SUSTAIN
| Trial | Drug | Duration | HbA1c reduction | Weight reduction | Comparator |
|---|---|---|---|---|---|
| SUSTAIN-6 | Semaglutide 0.5/1mg | 104 weeks | −1.0 / −1.4% | −3.6 / −4.9kg | Placebo (CVOT primary) |
| SURPASS-1 (2021) | Tirzepatide 5/10/15mg | 40 weeks | −1.87 / −1.89 / −2.07% | −7.0 / −7.8 / −9.5kg | Placebo |
| SURPASS-2 (2021) | Tirzepatide 5/10/15mg vs Sema 1mg | 40 weeks | −2.01 / −2.24 / −2.30% vs −1.86% | −7.6 / −9.3 / −11.2kg vs −5.7kg | Semaglutide 1mg directly |
| SURPASS-3 (2021) | Tirzepatide 5/10/15mg vs insulin degludec | 52 weeks | −1.93 / −2.20 / −2.37% vs −1.34% | −7.5 / −10.7 / −12.9kg vs +2.3kg | Insulin (weight divergence dramatic) |
| SURPASS-CVOT (2024) | Tirzepatide 5/10/15mg vs dulaglutide | ~3 years | Improved vs comparator | −6.7 / −9.3 / −11.2kg vs −1.0kg | Dulaglutide 1.5mg (GLP-1R agonist) |
SURPASS-2 is the most important glycaemic comparison for researchers: it directly compares tirzepatide at three doses against semaglutide 1mg in a head-to-head T2D trial. All three tirzepatide doses achieved greater HbA1c reductions than semaglutide 1mg; the 10mg and 15mg doses also achieved greater weight reduction. This is the strongest clinical evidence that dual GIP+GLP-1R agonism produces superior metabolic outcomes to selective GLP-1R agonism in T2D.
Cardiovascular Outcomes Data
Semaglutide has more extensive CVOT data: SUSTAIN-6 (2016, SC), PIONEER-6 (2019, oral), SOUL (2024, oral), and SELECT (2023) — with SELECT providing the most important finding: 20% MACE reduction in non-diabetic obese patients. Tirzepatide’s CVOT data is more recent: SURPASS-CVOT (2024) demonstrated non-inferiority vs dulaglutide. Dedicated tirzepatide MACE superiority data (SURMOUNT-MMO) is still pending — this is the key open cardiovascular research question for tirzepatide.
For cardiovascular mechanistic research, semaglutide currently has the deeper evidence base. For weight reduction mechanistic research and dual GIP+GLP-1R biology, tirzepatide is the appropriate tool.
Research Applications: When to Use Each
| Research goal | Preferred compound | Rationale |
|---|---|---|
| Selective GLP-1R agonism reference standard | Semaglutide | Most extensively documented selective GLP-1R agonist; deepest CVOT evidence base |
| Dual GIP+GLP-1R pharmacology | Tirzepatide | Purpose-built dual agonist; the only approved balanced GIPR/GLP-1R co-agonist |
| Maximum weight reduction in rodent obesity model | Tirzepatide (or retatrutide) | Phase 3 and preclinical data shows greater weight reduction than semaglutide |
| Cardiovascular GLP-1R mechanism research | Semaglutide | SELECT, SOUL, SUSTAIN-6 provide deeper cardiac mechanism research context |
| GIP receptor contribution to metabolic outcomes | Tirzepatide vs semaglutide parallel | Comparing the two isolates the GIP receptor contribution by subtraction |
| Oral GLP-1R agonism | Semaglutide (oral / Rybelsus) or orforglipron | Sema requires fasting; orforglipron does not — see oral vs injectable guide |
Frequently Asked Questions
Does tirzepatide cause more weight loss than semaglutide?
Phase 3 clinical trial data shows tirzepatide produces greater mean weight reduction than semaglutide at equivalent study durations. The SURMOUNT-1 trial (tirzepatide) documented up to 22.5% mean body weight reduction at 72 weeks, while STEP-1 (semaglutide 2.4mg) documented approximately 14.9% at 68 weeks. The direct head-to-head SURMOUNT-5 trial (2025) confirmed tirzepatide produced significantly greater weight reduction than semaglutide 2.4mg in obese patients — the first prospective head-to-head CVOT data.
What is the mechanism difference between tirzepatide and semaglutide?
Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP receptor (GIPR) and GLP-1 receptor co-agonist. The additional GIPR component in tirzepatide provides additive insulin secretion stimulation, independently activates adipose lipolysis and energy expenditure pathways, and may enhance GLP-1R sensitisation in hypothalamic appetite circuits. The combined GIP+GLP-1 receptor activation is the proposed mechanism behind tirzepatide’s greater weight reduction vs selective GLP-1R agonism.
Is tirzepatide better than semaglutide for type 2 diabetes?
Phase 3 data from SURPASS (tirzepatide) and SUSTAIN (semaglutide) programs shows tirzepatide producing greater HbA1c reductions (up to 2.58% vs approximately 1.8–2.0% for semaglutide 1mg at comparable timepoints) and greater body weight reduction. SURPASS-2 directly compared tirzepatide 5, 10, and 15mg vs semaglutide 1mg in T2D — all tirzepatide doses produced superior HbA1c reduction; 10mg and 15mg produced superior weight reduction.
What are the side effects of tirzepatide vs semaglutide?
Both tirzepatide and semaglutide share the characteristic GLP-1R agonist GI side effect profile: nausea, vomiting, diarrhoea, and constipation — typically highest during dose escalation and diminishing over time. Tirzepatide’s GI tolerability profile is broadly similar to semaglutide in trial data. Both were associated with low rates of serious adverse events in Phase 3. Neither is associated with increased cardiovascular risk; both have neutral to beneficial cardiovascular profiles in CVOT data.
Is there a head-to-head trial of tirzepatide vs semaglutide?
Yes. SURMOUNT-5 (2025) was a prospective head-to-head randomised trial comparing tirzepatide vs semaglutide 2.4mg in obese patients without diabetes. Tirzepatide produced significantly greater body weight reduction — approximately 20.2% vs 13.7% mean reduction at 72 weeks — the first direct head-to-head trial data confirming tirzepatide’s weight reduction advantage in a prospective setting.
Tirzepatide · Semaglutide · Retatrutide · Orforglipron